Subscribe To
VIVO / Bull of the Day: Meridian Bioscience (VIVO)
VIVO News
By Investors Business Daily
November 17, 2022
Medical Devices Stock Pumps Up Buy Point With New Innovations
After launching three new products and posting a second quarter of rising EPS growth, medical devices leader Merit Medical Systems is probing a new bu more_horizontal
By InvestorPlace
July 7, 2022
Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement
VIVO stock is a hot topic on Wall Street today, not just because Meridian Biosciences released a fiscal update, but also due to takeover news. The pos more_horizontal
By Seeking Alpha
July 5, 2022
Meridian Bioscience Is Not Your Average Life Science Company
100% technical buy signals. 8 new highs and up 15.79% in the last month. more_horizontal
By PRNewsWire
May 23, 2022
Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference
CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and lif more_horizontal
By Benzinga
May 6, 2022
Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History
Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segmen more_horizontal
By Seeking Alpha
May 6, 2022
Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q2 2022 Results - Earnings Call Transcript
Meridian Bioscience, Inc. (NASDAQ:VIVO ) Q2 2022 Earnings Conference Call May 6, 2022 10:00 AM ET Corporate Participants Charlie Wood - Vice President more_horizontal
By Zacks Investment Research
May 5, 2022
Meridian Bioscience (VIVO) is on the Move, Here's Why the Trend Could be Sustainable
Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound s more_horizontal
By Zacks Investment Research
April 29, 2022
Meridian Bioscience (VIVO) Expected to Beat Earnings Estimates: Should You Buy?
Meridian Bioscience (VIVO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared more_horizontal